Corbus Pharmaceuticals Holdings, Inc.
CRBPHealthcareNASDAQBiotechnology · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
Part of the healthcare sector, Corbus Pharmaceuticals Holdings, Inc. (CRBP) is listed under Biotechnology. The company carries a $85.5M market cap, placing it firmly in the micro-cap category. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Market Cap
$85.5M
Beta
2.63
P/E (TTM)
—
P/E (Fwd)
-0.80
EPS (TTM)
$-6.11
EPS (Fwd)
$-5.51
ROE
-95.6%
ROA
-53.0%
Cash
$117.9M
Total Debt
$4.3M
Free CF
-$49.6M
52W Change
-75.1%
Annual Financials
Cash vs Debt
Where CRBP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CRBP finished 50.17% below its 150-day moving average ($8.95) and 49.32% below its 200-day moving average ($8.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRBP overbought or oversold?
At the October 20, 2026 close, CRBP's RSI(14) was 15.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $117.9M in cash and $4.3M in debt, CRBP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$49.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -95.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, CRBP tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRBP.